Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG as a Booster for TDaP-IPV Vaccination
NCT02771782Phase 4Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2015
- Primary completion
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bcg vaccine in pertussis and Tuberculosis (TB), sponsored by Radboud University Medical Center. Primary endpoint: Antibody response to TDaP-IPV at 1 year. Status: unknown.
02
Drugs
bcg vaccine
03
Conditions
pertussisTuberculosis (TB)
Beyond the preview
Go deeper on NCT02771782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771782.